Abbott Laboratories (ABT) Free Cash Flow (FCF): $7.39B
The free cash flow (FCF) for Abbott Laboratories (ABT) is $7.39B. It is above its 12-month average by 7.59% ($6.87B).
ABT Free Cash Flow (FCF) Chart
ABT Average Free Cash Flow (FCF) Chart
ABT Current vs Average Free Cash Flow (FCF) Chart
ABT Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$7.39B
FREE CASH FLOW (FCF) AVG TTM
$6.87B
FREE CASH FLOW (FCF) AVG 3Y
$6.65B
FREE CASH FLOW (FCF) AVG 5Y
$6.83B
FREE CASH FLOW (FCF) AVG 10Y
$5.34B
FREE CASH FLOW (FCF) AVG 15Y
$5.39B
FREE CASH FLOW (FCF) AVG 20Y
$5.24B
CURRENT VS TTM AVG
+7.59%
CURRENT VS 3Y AVG
+11.17%
CURRENT VS 5Y AVG
+8.27%
CURRENT VS 10Y AVG
+38.44%
CURRENT VS 15Y AVG
+37.18%
CURRENT VS 20Y AVG
+41.20%
FCF Analysis
Free Cash Flow (TTM)
$7.39B
FCF Yield
4.63%
Price/FCF
21.6
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Abbott Laboratories Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Abbott Laboratories Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Abbott Laboratories (ABT)?
- The free cash flow (FCF) for ABT stock is $7.39B.
- What is the TTM average free cash flow (FCF) for Abbott Laboratories (ABT)?
- The TTM average free cash flow (FCF) for ABT stock is $6.87B.
- What is the 3Y average free cash flow (FCF) for Abbott Laboratories (ABT)?
- The 3Y average free cash flow (FCF) for ABT stock is $6.65B.
- What is the 5Y average free cash flow (FCF) for Abbott Laboratories (ABT)?
- The 5Y average free cash flow (FCF) for ABT stock is $6.83B.
- What is the 10Y average free cash flow (FCF) for Abbott Laboratories (ABT)?
- The 10Y average free cash flow (FCF) for ABT stock is $5.34B.
- What is the 15Y average free cash flow (FCF) for Abbott Laboratories (ABT)?
- The 15Y average free cash flow (FCF) for ABT stock is $5.39B.
- What is the 20Y average free cash flow (FCF) for Abbott Laboratories (ABT)?
- The 20Y average free cash flow (FCF) for ABT stock is $5.24B.
Abbott Laboratories Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2025-12-31 | $7.39B |
| 2024-12-31 | $6.35B |
| 2023-12-31 | $5.06B |
| 2022-12-31 | $7.80B |
| 2021-12-31 | $8.65B |
| 2020-12-31 | $5.72B |
| 2019-12-31 | $4.50B |
| 2018-12-31 | $4.91B |
| 2017-12-31 | $4.43B |
| 2016-12-31 | $2.08B |
| 2015-12-31 | $1.86B |
| 2014-12-31 | $2.60B |
| 2013-12-31 | $2.18B |
| 2012-12-31 | $7.52B |
| 2011-12-31 | $7.48B |
| 2010-12-31 | $7.72B |
| 2009-12-31 | $6.19B |
| 2008-12-31 | $6.06B |
| 2007-12-31 | $3.53B |
| 2006-12-31 | $3.99B |
| 2005-12-31 | $3.97B |
| 2004-12-31 | $3.12B |
| 2003-12-31 | $2.50B |
| 2002-12-31 | $2.89B |
| 2001-12-31 | $2.40B |
| 2000-12-31 | $2.06B |
| 1999-12-31 | $1.95B |
| 1998-12-31 | $1.49B |
| 1997-12-31 | $1.42B |
| 1996-12-31 | $1.43B |
Related Metrics
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford